Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.00    -0.25 (-1.75%)
Bid:
13.50
Ask:
14.50
Spread: 1.00 (7.407%)
Market Cap: £11.55m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Nandi Proteins Ltd: Further Successful Fundraising

7 Mar 2016 07:00

RNS Number : 1514R
Frontier IP Group plc
07 March 2016
 

 

AIM: FIPP

7 March 2016

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Nandi Proteins Limited - Further Successful Fundraising

 

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that the latest funding round for its portfolio company Nandi Proteins Limited ("Nandi") has been achieved, at a valuation of £7.57 million, at twice the price per share of the previous fundraising in November 2014.

 

Nandi has raised £250,000 from new and existing investors, which will result in Frontier IP's holding in Nandi being revalued upwards by £0.78 million. The increase will be recognised in the Group's forthcoming half-year results for the period ended 31 December 2015. Frontier IP retains a 20.8% holding in the issued share capital of Nandi.

 

Nandi, which spun out from Heriot-Watt University, Edinburgh, is commercialising a patented protein process technology which can reduce sugars, fats and emulsifiers in processed food without adversely impacting taste and texture. Nandi's technology is being rolled out at a time when food companies are under increasing legislative pressure to reduce the level of these ingredients in their products. Nandi's technology enables food industry customers to remain competitive in response to healthier eating trends using sustainable, naturally-occurring proteins in food manufacture.

 

This funding will enable Nandi to develop further its relationships with multinational food companies, where strong interest has already been shown, extend its product range and prepare for scale-up.

 

Dr. Lydia Campbell, Chief Technology Officer of Nandi, said:

 

"Frontier IP has been instrumental in successfully securing this fundraising which will leverage our relationships in the food sector at a time when the industry is seeking effective ways to address consumer health. The potential of Nandi's technology to address the health of consumers is increasingly recognised by major food companies and we are now investing to commercialise our technology to address this demand."

 

Neil Crabb, Chief Executive of Frontier IP, said:

 

"Nandi's technology enables food companies to improve the nutritional profile of their products. Frontier IP has been delighted to assist with Nandi's funding round and will continue to deploy its resources to support the rapid commercialisation of this timely technology which offers a solution to such an urgent requirement for the food industry."

 

 

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

David Foreman, Catherine Leftley, Corporate Finance

David Banks, Corporate Broking

Peterhouse Corporate Finance Limited

(Joint Broker)

T: 020 7469 0935

Lucy Williams

Kreab

(Financial PR)

T: 020 7074 1800

Robert Speed, Matthew Jervois

 

 

Notes to Editor:

 

About Frontier IP Group plc

www.frontierip.co.uk.

Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses.

 

About Nandi Proteins Limited

Nandi exploits its patented technology and know-how to improve the functionality of protein-based food ingredients. The structural change in proteins during heat treatment is manipulated to add value to common naturally occurring proteins, which have a wide range of applications in the food industry. Nandi's products are particularly effective as sugar, fat and emulsifier replacers enabling lower fat, lower sugar and clean-label product.

 

Dr. Lydia Campbell, Chief Technology Officer of Nandi, has led the development of Nandi's breakthrough technology. She holds a PhD in Biochemistry from the University of Witwatersrand, South Africa and has completed a post-doctoral study in protein chemistry. Lydia has extensive R&D and product application experience gained during 9 years with Nestle Switzerland, Germany and South Africa.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMMGGFKDRGVZM
Date   Source Headline
23rd Jun 20267:00 amRNSPosting of Circular and Notice of General Meeting
19th Jun 20267:00 amRNSResult of Retail Offer
17th Jun 20267:00 amRNSResult of Placing and Subscription
16th Jun 20265:20 pmRNSRetail Offer
16th Jun 20264:58 pmRNSProposed Placing and Subscription
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.